TW202400135A - 包含阿替卡普蘭之組成物 - Google Patents

包含阿替卡普蘭之組成物 Download PDF

Info

Publication number
TW202400135A
TW202400135A TW112108149A TW112108149A TW202400135A TW 202400135 A TW202400135 A TW 202400135A TW 112108149 A TW112108149 A TW 112108149A TW 112108149 A TW112108149 A TW 112108149A TW 202400135 A TW202400135 A TW 202400135A
Authority
TW
Taiwan
Prior art keywords
weight
atecaplan
pharmaceutical composition
treatment
hours
Prior art date
Application number
TW112108149A
Other languages
English (en)
Chinese (zh)
Inventor
尼可拉斯 高瓦特斯
馬克 舒米特
維尼納 波帕瓦
亞當 薩維茲
拉瑪 梅爾寇特
偉恩 德瑞維茲
斯里哈里 古帕
達瑞爾 潘柏頓
恰卡拉德哈 萊吉席堤
艾維 凱茲克
馬哈許 山姆塔尼
湯姆 哈比爾查特斯
吉爾特 范德阿佛特
馬修 拉夫林根
勞拉 馬汀尼茲馬可斯
塔蒂雅娜 馬爾科齊
卡塔琳娜 約基切維奇
Original Assignee
美商健生醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健生醫藥公司 filed Critical 美商健生醫藥公司
Publication of TW202400135A publication Critical patent/TW202400135A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112108149A 2022-03-07 2023-03-06 包含阿替卡普蘭之組成物 TW202400135A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317471P 2022-03-07 2022-03-07
US63/317,471 2022-03-07

Publications (1)

Publication Number Publication Date
TW202400135A true TW202400135A (zh) 2024-01-01

Family

ID=85980700

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112108149A TW202400135A (zh) 2022-03-07 2023-03-06 包含阿替卡普蘭之組成物

Country Status (16)

Country Link
US (3) US20230277500A1 (https=)
EP (1) EP4489730B1 (https=)
JP (1) JP2025508069A (https=)
KR (1) KR20240152410A (https=)
CN (1) CN119156202A (https=)
AU (1) AU2023231767A1 (https=)
CA (1) CA3254546A1 (https=)
CL (1) CL2024002648A1 (https=)
CO (1) CO2024012454A2 (https=)
ES (1) ES3064226T3 (https=)
IL (1) IL315415A (https=)
JO (1) JOP20240196A1 (https=)
MX (1) MX2024010977A (https=)
TW (1) TW202400135A (https=)
UY (1) UY40173A (https=)
WO (1) WO2023170554A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
WO2000069858A1 (en) 1999-05-12 2000-11-23 F. Hoffmann-La Roche Ag Imidazodiazepine derivative
JP2004510789A (ja) 2000-10-05 2004-04-08 モーラー，ハンス 選択的抗不安治療薬
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
US7396943B2 (en) 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
CN1756746A (zh) 2003-03-07 2006-04-05 伊莱利利公司 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
BRPI0417156A (pt) 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
EP1727788B1 (en) 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
JP2007529523A (ja) 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
CA2557794A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
WO2009094260A1 (en) 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
BR112013002846A2 (pt) 2010-08-05 2016-06-07 Conrig Pharma Aps derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
EP2773352B1 (en) 2011-12-09 2017-06-28 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
MX368870B (es) 2013-12-20 2019-10-21 H Lundbeck As Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
US10377698B2 (en) 2015-03-30 2019-08-13 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
US10709685B2 (en) 2015-05-28 2020-07-14 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
SI3881833T1 (sl) * 2015-06-30 2024-03-29 Genentech, Inc., Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet
WO2017218518A1 (en) 2016-06-13 2017-12-21 Board Of Regents Of The University Of Texas System Pharmaceutical compositions and methods for treatment of pain
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
JP7048572B6 (ja) 2016-09-16 2023-12-20 リサーチ トライアングル インスティテュート テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
ES2926533T3 (es) 2017-03-17 2022-10-26 Scripps Research Inst Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos
PH12018000077B1 (en) * 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
WO2019183556A1 (en) 2018-03-23 2019-09-26 University Of Kansas Cyclic tetrapeptide analogs
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
JP2022505676A (ja) 2018-10-23 2022-01-14 ブラックソーン セラピューティクス インコーポレイテッド 患者のスクリーニング、診断、及び層別化のためのシステム及び方法
US20200171025A1 (en) * 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2022268720A1 (en) * 2021-05-04 2023-12-21 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170547A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Also Published As

Publication number Publication date
MX2024010977A (es) 2024-12-06
KR20240152410A (ko) 2024-10-21
IL315415A (en) 2024-11-01
US12201610B2 (en) 2025-01-21
US20240269110A1 (en) 2024-08-15
CO2024012454A2 (es) 2024-09-30
ES3064226T3 (en) 2026-04-23
UY40173A (es) 2023-09-29
AU2023231767A1 (en) 2024-10-24
CL2024002648A1 (es) 2025-01-24
US20230277500A1 (en) 2023-09-07
CN119156202A (zh) 2024-12-17
CA3254546A1 (en) 2023-09-14
EP4489730B1 (en) 2026-01-21
WO2023170554A1 (en) 2023-09-14
JP2025508069A (ja) 2025-03-21
JOP20240196A1 (ar) 2024-09-05
EP4489730C0 (en) 2026-01-21
US20250228819A1 (en) 2025-07-17
EP4489730A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
US12201610B2 (en) Compositions comprising aticaprant
CA2964504C (en) Oral dosage form comprising a cyclopropanecarboxamide derivative for use in treating insomnia
TW202313003A (zh) 用於治療憂鬱之組成物及方法
US12419859B2 (en) Compositions and methods for the treatment of depression
TW202345795A (zh) 純質形式之結晶型阿替卡普蘭
US20250325515A1 (en) Forms Of Aticaprant
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
EP3917518A1 (en) The use of an mglur5 antagonist for treating opioid analgesic tolerance
US20250221960A1 (en) Compositions and methods for the treatment of depression
US20240238245A1 (en) Compositions and methods for the treatment of depression
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
CN121969364A (zh) 用于在治疗重性抑郁障碍中使用的包含阿替卡普兰的组合物
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
TW201244717A (en) Treatment of attention deficit/hyperactivity disease
EA046106B1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТА mGluR5 ДЛЯ ЛЕЧЕНИЯ ТОЛЕРАНТНОСТИ К ОПИОИДНЫМ АНАЛЬГЕТИКАМ
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for
PRESCRIBED Change for